JP2018507200A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507200A5 JP2018507200A5 JP2017541753A JP2017541753A JP2018507200A5 JP 2018507200 A5 JP2018507200 A5 JP 2018507200A5 JP 2017541753 A JP2017541753 A JP 2017541753A JP 2017541753 A JP2017541753 A JP 2017541753A JP 2018507200 A5 JP2018507200 A5 JP 2018507200A5
- Authority
- JP
- Japan
- Prior art keywords
- tablet formulation
- solid tablet
- formulation according
- excipient
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007916 tablet composition Substances 0.000 claims 60
- 239000007787 solid Substances 0.000 claims 58
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 26
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 24
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 21
- 229960001681 Croscarmellose Sodium Drugs 0.000 claims 20
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 18
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 18
- 229960001507 ibrutinib Drugs 0.000 claims 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 15
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 15
- 239000008108 microcrystalline cellulose Substances 0.000 claims 15
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 15
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 13
- 235000019359 magnesium stearate Nutrition 0.000 claims 13
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 13
- 229960001375 Lactose Drugs 0.000 claims 12
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 12
- 239000008101 lactose Substances 0.000 claims 12
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 11
- 239000003085 diluting agent Substances 0.000 claims 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 6
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 6
- 239000007884 disintegrant Substances 0.000 claims 5
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 claims 4
- 229960001021 Lactose Monohydrate Drugs 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 230000036888 Average AUC Effects 0.000 claims 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 2
- 229960005168 Croscarmellose Drugs 0.000 claims 2
- 229960000913 Crospovidone Drugs 0.000 claims 2
- 229940057948 Magnesium stearate Drugs 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000008121 dextrose Substances 0.000 claims 2
- 235000020828 fasting Nutrition 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 claims 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229960002900 Methylcellulose Drugs 0.000 claims 1
- 239000004368 Modified starch Substances 0.000 claims 1
- 229940005550 Sodium alginate Drugs 0.000 claims 1
- 229940032147 Starch Drugs 0.000 claims 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 Xylitol Drugs 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 235000011132 calcium sulphate Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000004927 clay Substances 0.000 claims 1
- 229910052570 clay Inorganic materials 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 229940080313 sodium starch Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
Claims (41)
- イブルチニブと1つ以上の薬学的に許容される賦形剤とを含む固形錠剤製剤であって、イブルチニブが、化合物1の構造を有する化合物であり、
- 前記固形錠剤製剤が、約50%w/w〜約90%w/wのイブルチニブ、約50%w/w〜約80%w/wのイブルチニブ、約60%w/w〜約80%w/wのイブルチニブ、または約60%w/w〜約75%w/wのイブルチニブを含む高負荷の固形錠剤製剤である、請求項1に記載の固形錠剤製剤。
- イブルチニブは、1錠剤当たり約35mg〜約840mgの量である、請求項1に記載の固形錠剤製剤。
- イブルチニブは、錠剤中、約35mg、約70mg、約140mg、約280mg、約420mg、約560mg、または約840mgの量である、請求項3に記載の固形錠剤製剤。
- イブルチニブは微粒子形態である、請求項1に記載の固形錠剤製剤。
- イブルチニブの粒径は約30ミクロンまたは30ミクロン未満であり、イブルチニブの粒径は約10ミクロンまたは10ミクロン未満であり、あるいは、イブルチニブの粒径は1ミクロン未満である、請求項1に記載の固形錠剤製剤。
- 少なくとも1つの賦形剤は希釈剤である、請求項1に記載の固形錠剤製剤。
- 前記希釈剤は、ラクトース、スクロース、デキストロース、デキストレート、マルトデキストリン、マンニトール、キシリトール、ソルビトール、シクロデキストリン、リン酸カルシウム、硫酸カルシウム、デンプン、化工デンプン、セルロース、微結晶性セルロース、微小セルロース、及びタルクからなる群から選択される、請求項7に記載の固形錠剤製剤。
- 前記希釈剤はセルロースである、請求項7に記載の固形錠剤製剤。
- 前記希釈剤はラクトースである、請求項7に記載の固形錠剤製剤。
- 前記希釈剤は微結晶性セルロースである、請求項7に記載の固形錠剤製剤。
- 前記希釈剤はラクトースと微結晶性セルロースを含む、請求項7に記載の固形錠剤製剤。
- 少なくとも1つの賦形剤は希釈剤であり、前記希釈剤はラクトースであり、かつ、ラクトースは、約5%w/w〜約20%w/w、約8%w/w〜約20%w/w、または約8%w/w〜約15%w/wの量で存在する、請求項1に記載の固形錠剤製剤。
- 少なくとも1つの賦形剤は希釈剤であり、前記希釈剤は微結晶性セルロースであり、前記微結晶性セルロースは、約5%w/w〜約20%w/w、約8%w/w〜約20%w/w、約8%w/w〜約15%w/w、約1%w/w〜約10%w/w、または約1%w/w〜約6%w/wの量で存在する、請求項1に記載の固形錠剤製剤。
- 少なくとも1つの賦形剤は滑沢剤である、請求項1に記載の固形錠剤製剤。
- 滑沢剤はステアリン酸マグネシウムである、請求項15に記載の固形錠剤製剤。
- 前記固形錠剤製剤は少なくとも50%w/wのイブルチニブを含む固形錠剤製剤であり、少なくとも1つの賦形剤は希釈剤であり、および、少なくとも1つの賦形剤は滑沢剤である、請求項1に記載の固形錠剤製剤。
- 少なくとも1つの賦形剤は崩壊剤である、請求項1に記載の固形錠剤製剤。
- 前記崩壊剤は、天然デンプン、プレゼラチン化デンプン、デンプンナトリウム、メチル結晶性セルロース、メチルセルロース、クロスカルメロース、クロスカルメロースナトリウム、架橋カルボキシメチルセルロースナトリウム、架橋カルボキシメチルセルロース、架橋クロスカルメロース、デンプングリコール酸ナトリウム等の架橋デンプン、クロスポビドン等の架橋ポリマー、架橋ポリビニルピロリドン、アルギン酸ナトリウム、粘土、及びゴムからなる群から選択される、請求項18に記載の固形錠剤製剤。
- 前記崩壊剤はクロスカルメロースナトリウムである、請求項18に記載の固形錠剤製剤。
- 少なくとも1つの賦形剤は崩壊剤であり、前記崩壊剤はクロスカルメロースナトリウムであり、クロスカルメロースナトリウムは、約0%w/w〜約20%w/w、約1%w/w〜約10%w/w、約5%w/w〜約10%w/w、約6%w/w〜約8%w/w、約4%w/w〜約6%w/w、または約2%w/w〜約4%w/wの量で存在する、請求項1に記載の固形錠剤製剤。
- 少なくとも1つの賦形剤は結合剤である、請求項1に記載の固形錠剤製剤。
- 前記結合剤はポリビニルピロリドンまたはヒドロキシプロピルセルロースである、請求項22に記載の固形錠剤製剤。
- 少なくとも1つの賦形剤は結合剤であり、結合剤はヒドロキシプロピルセルロースであり、および、ヒドロキシプロピルセルロースは、約0%w/w〜約10%w/w、約0%w/w〜約5%w/w、約0%w/w〜約2%w/w、約0.1%w/w〜約1.1%w/w、または約0.1%w/w〜約1%w/wの量で存在する、請求項22に記載の固形錠剤製剤。
- 少なくとも1つの賦形剤は結合剤であり、結合剤はポリビニルピロリドンであり、および、ポリビニルピロリドンは、約0%w/w〜約10%w/wまたは約1%w/w〜約5%w/wの量で存在する、請求項22に記載の固形錠剤製剤。
- 少なくとも1つの賦形剤は界面活性剤である、請求項1に記載の固形錠剤製剤。
- 前記固形錠剤製剤は1つ以上の流動促進剤をさらに含む、請求項1に記載の固形錠剤製剤。
- 前記固形錠剤製剤は、顆粒内賦形剤及び顆粒外賦形剤を含み、前記顆粒内賦形剤は、ラクトース、微結晶性セルロース、クロスカルメロースナトリウム、及びヒドロキシプロピルセルロースを含み、前記顆粒外賦形剤は、クロスカルメロースナトリウム、ラウリル硫酸ナトリウム、コロイド状二酸化ケイ素、及びステアリン酸マグネシウムを含む、請求項1に記載の固形錠剤製剤。
- 前記固形錠剤製剤は、顆粒内賦形剤及び顆粒外賦形剤を含み、
前記顆粒内賦形剤は、
約5%w/w〜約20%w/w、約8%w/w〜約15%w/w、または約8%w/w〜約14%w/wの量のラクトースと、
約5%w/w〜約20%w/w、約8%w/w〜約20%w/w、または約8%w/w〜約15%w/wの量の微結晶性セルロースと、
約0%w/w〜約10%w/w、約2%w/w〜約5%w/w、または約2%w/w〜約4%w/wの量のクロスカルメロースナトリウムと、
約0%w/w〜約2%w/w、約0.1%w/w〜約1.1%w/w、または約0.1%w/w〜約1%w/wの量のヒドロキシプロピルセルロースと、を含み、
前記顆粒外賦形剤は、
約0%w/w〜約5%w/w、約2%w/w〜約5%w/w、または約2%w/w〜約4%w/wの量のクロスカルメロースナトリウムと、
約0%w/w〜約10%w/w、約4%w/w〜約8%w/w、または約5%w/w〜約6%w/wの量のラウリル硫酸ナトリウムと、
約0.1%w/w〜約1.5%w/w、約0.4%w/w〜約0.8%w/w、または約0.5%w/w〜約0.6%w/wの量のコロイド状二酸化ケイ素と、
約0.1%w/w〜約1.5%w/w、約0.4%w/w〜約0.8%w/w、または約0.5%w/w〜約0.6%w/wの量のステアリン酸マグネシウムと、を含む、請求項1に記載の固形錠剤製剤。 - 前記固形錠剤製剤は、顆粒内賦形剤及び顆粒外賦形剤を含み、前記顆粒内賦形剤は、ラクトース、ラウリル硫酸ナトリウム、ポリビニルピロリドン、及びクロスカルメロースナトリウムを含み、前記顆粒外賦形剤は、クロスカルメロースナトリウム、ラウリル硫酸ナトリウム、微結晶性セルロース、コロイド状二酸化ケイ素、及びステアリン酸マグネシウムを含む、請求項1に記載の固形錠剤製剤。
- 前記固形錠剤製剤は、顆粒内賦形剤及び顆粒外賦形剤を含み、
前記顆粒内賦形剤は、
約10%w/w〜約20%w/wまたは約12%w/w〜約15%w/wの量のラクトースと、
約0%w/w〜約5%w/wまたは約1%w/w〜約3%w/wの量のポリビニルピロリドンと、
約1%w/w〜約10%w/wまたは約3%w/w〜約7%w/wの量のクロスカルメロースナトリウムと、
約0%w/w〜約2%w/wまたは約0.5%w/w〜約1.5%w/wの量のラウリル硫酸ナトリウムと、を含み、
前記顆粒外賦形剤は、
約0%w/w〜約5%w/wまたは約1%w/w〜約3%w/wの量のクロスカルメロースナトリウムと、
約0%w/w〜約10%w/wまたは約0%w/w〜約4%w/wの量のラウリル硫酸ナトリウムと、
約1%w/w〜約10%w/wまたは約2%w/w〜約5%w/wの量の微結晶性セルロースと、
約0.4%w/w〜約0.8%w/wまたは約0.5%w/w〜約0.6%w/wの量のコロイド状二酸化ケイ素と、
約0.4%w/w〜約0.8%w/wまたは約0.5%w/w〜約0.6%w/wの量のステアリン酸マグネシウムと、を含む、請求項1に記載の固形錠剤製剤。 - a)約69%w/w〜約71%w/wのイブルチニブと、
b)約13%w/w〜約15%w/wのラクトース一水和物と、
c)約2%w/w〜約5%w/wの微結晶性セルロースと、
d)約1%w/w〜約3%w/wのポリビニルピロリドンと、
e)約6%w/w〜約8%w/wのクロスカルメロースナトリウムと、
f)約1%w/w〜約4%w/wのラウリル硫酸ナトリウムと、
g)約0.4%w/w〜約0.6%w/wのコロイド状二酸化ケイ素と、
h)約0.4%w/w〜約0.6%w/wのステアリン酸マグネシウムと、を含む、請求項1に記載の固形錠剤製剤。 - a)約70%w/wのイブルチニブと、
b)約14%w/wのラクトース一水和物と、
c)約5%w/wの微結晶性セルロースと、
d)約2%w/wのポリビニルピロリドンと、
e)約7%w/wのクロスカルメロースナトリウムと、
f)約1%w/wのラウリル硫酸ナトリウムと、
g)約0.5%w/wのコロイド状二酸化ケイ素と、
h)約0.5%w/wのステアリン酸マグネシウムと、を含む、請求項1に記載の固形錠剤製剤。 - a)約70%w/wのイブルチニブと、
b)約14%w/wのラクトース一水和物と、
c)約2%w/wの微結晶性セルロースと、
d)約2%w/wのポリビニルピロリドンと、
e)約7%w/wのクロスカルメロースナトリウムと、
f)約4%w/wのラウリル硫酸ナトリウムと、
g)約0.5%w/wのコロイド状二酸化ケイ素と、
h)約0.5%w/wのステアリン酸マグネシウムと、を含む、請求項1に記載の固形錠剤製剤。 - 前記固形錠剤製剤は、
a)約65%w/w〜約75%w/wのイブルチニブと、
b)約14%w/w〜約18%w/wのラクトース一水和物と、
c)約1%w/w〜約3%w/wのポリビニルピロリドンと、
d)約0.5%w/w〜約1.5%w/wのラウリル硫酸ナトリウムと、
e)約5%w/w〜約15%w/wのクロスポビドンと、
f)約0.3%w/w〜約0.7%w/wのコロイド状二酸化ケイ素と、
g)約0.3%w/w〜約0.7%w/wのステアリン酸マグネシウムと、を含む、請求項1に記載の固形錠剤製剤。 - 前記固形錠剤製剤は、
a)約59%w/w〜約61%w/wのイブルチニブと、
b)約13%w/w〜約15%w/wのラクトースと、
c)約13%w/w〜約15%w/wの微結晶性セルロースと、
d)約4%w/w〜約6%w/wのクロスカルメロースナトリウムと、
e)約5%w/w〜約7%w/wのラウリル硫酸ナトリウムと、
f)約0.4%w/w〜約0.6%w/wのコロイド状二酸化ケイ素と、
g)約0.4%w/w〜約0.6%w/wのステアリン酸マグネシウムと、を含む、請求項1に記載の固形錠剤製剤。 - 前記固形錠剤製剤は、
a)約59%w/w〜約61%w/wのイブルチニブと、
b)約13%w/w〜約14%w/wのラクトースと、
c)約13%w/w〜約14%w/wの微結晶性セルロースと、
d)約2%w/w〜約3%w/wのクロスカルメロースナトリウム(顆粒内)と、
e)約0.8%w/w〜約1.2%w/wのヒドロキシプロピルセルロースと、
f)約2%w/w〜約3%w/wのクロスカルメロースナトリウム(顆粒外)と、
g)約5.5%w/w〜約6.5%w/wのラウリル硫酸ナトリウムと、
h)約0.4%w/w〜約0.6%w/wのコロイド状二酸化ケイ素と、
i)約0.4%w/w〜約0.6%w/wのステアリン酸マグネシウムと、を含む、請求項1に記載の固形錠剤製剤。 - 前記固形錠剤製剤は、
a)約69%w/w〜約71%w/wのイブルチニブと、
b)約8%w/w〜約9%w/wのラクトースと、
c)約8%w/w〜約9%w/wの微結晶性セルロースと、
d)約2.5%w/w〜約3.5%w/wのクロスカルメロースナトリウム(顆粒内)と、
e)約2.5%w/w〜約3.5%w/wのクロスカルメロースナトリウム(顆粒外)と、
g)約5.5%w/w〜約6.5%w/wのラウリル硫酸ナトリウムと、
h)約0.4%w/w〜約0.6%w/wのコロイド状二酸化ケイ素と、
i)約0.4%w/w〜約0.6%w/wのステアリン酸マグネシウムと、を含む、請求項1に記載の固形錠剤製剤。 - 前記固形錠剤製剤は、1日1回1錠の投与のために使用される、請求項1〜38のいずれか1項に記載の固形錠剤製剤。
- 絶食状態の健康なヒトの大人の集団に560mgのイブルチニブを送達するのに十分な量での固形錠剤製剤の1以上の錠剤の経口投与は、約465ng*h/mL+/−248ng*h/mLの平均AUC 0−∞ をもたらす、請求項1〜38のいずれか1項に記載の固形錠剤製剤。
- a.イブルチニブと、
b.1つ以上の薬学的に許容可能な賦形剤とを含む、固形錠剤製剤であって、
イブルチニブは少なくとも約50%w/wの量で存在し、および、
絶食状態の健康なヒトの大人の集団に560mgのイブルチニブを送達するのに十分な量での固形錠剤製剤の1以上の錠剤の経口投与は、約465ng*h/mL+/−248ng*h/mLの平均AUC 0−∞ をもたらす、固形錠剤製剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022106400A JP2022141701A (ja) | 2015-03-03 | 2022-06-30 | ブルトン型チロシンキナーゼ阻害剤の薬学的製剤 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562127717P | 2015-03-03 | 2015-03-03 | |
US62/127,717 | 2015-03-03 | ||
US201562193518P | 2015-07-16 | 2015-07-16 | |
US62/193,518 | 2015-07-16 | ||
PCT/US2016/020467 WO2016141068A1 (en) | 2015-03-03 | 2016-03-02 | Pharmaceutical formulations of bruton's tyrosine kinase inhibtor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022106400A Division JP2022141701A (ja) | 2015-03-03 | 2022-06-30 | ブルトン型チロシンキナーゼ阻害剤の薬学的製剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018507200A JP2018507200A (ja) | 2018-03-15 |
JP2018507200A5 true JP2018507200A5 (ja) | 2019-04-25 |
JP7149076B2 JP7149076B2 (ja) | 2022-10-06 |
Family
ID=56848552
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017541753A Active JP7149076B2 (ja) | 2015-03-03 | 2016-03-02 | ブルトン型チロシンキナーゼ阻害剤の薬学的製剤 |
JP2022106400A Pending JP2022141701A (ja) | 2015-03-03 | 2022-06-30 | ブルトン型チロシンキナーゼ阻害剤の薬学的製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022106400A Pending JP2022141701A (ja) | 2015-03-03 | 2022-06-30 | ブルトン型チロシンキナーゼ阻害剤の薬学的製剤 |
Country Status (25)
Country | Link |
---|---|
US (8) | US9655857B2 (ja) |
EP (2) | EP4338738A2 (ja) |
JP (2) | JP7149076B2 (ja) |
KR (1) | KR20170122220A (ja) |
CN (1) | CN107427498A (ja) |
AU (3) | AU2016226279B2 (ja) |
BR (2) | BR112017018931A2 (ja) |
CA (3) | CA2976695C (ja) |
DK (1) | DK3265084T3 (ja) |
FI (1) | FI3265084T3 (ja) |
HK (1) | HK1249015A1 (ja) |
HR (1) | HRP20240231T1 (ja) |
IL (2) | IL293284A (ja) |
LT (1) | LT3265084T (ja) |
MX (5) | MX2017011270A (ja) |
NZ (1) | NZ734446A (ja) |
PL (1) | PL3265084T3 (ja) |
PT (1) | PT3265084T (ja) |
RS (1) | RS65234B1 (ja) |
RU (1) | RU2017133990A (ja) |
SG (2) | SG10202102078VA (ja) |
SI (1) | SI3265084T1 (ja) |
TW (4) | TW202315634A (ja) |
WO (1) | WO2016141068A1 (ja) |
ZA (1) | ZA201907661B (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ717373A (en) | 2010-06-03 | 2017-11-24 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
CN104736178A (zh) | 2012-06-04 | 2015-06-24 | 药品循环公司 | 布鲁顿酪氨酸激酶抑制剂的晶形 |
BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
EP3060218A4 (en) * | 2013-10-25 | 2017-07-19 | Pharmacyclics LLC | Methods of treating and preventing graft versus host disease |
TW202228700A (zh) * | 2013-12-02 | 2022-08-01 | 美商製藥公司 | 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法 |
SG11201700849XA (en) * | 2014-08-07 | 2017-03-30 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor |
JP7149076B2 (ja) * | 2015-03-03 | 2022-10-06 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の薬学的製剤 |
AU2016235533B2 (en) | 2015-03-20 | 2019-08-15 | Inovio Pharmaceuticals, Inc. | Vaccines with CD40 ligand as an adjuvant |
KR102632745B1 (ko) * | 2015-04-06 | 2024-02-01 | 얀센 파마슈티카 엔브이 | 이브루티닙을 함유하는 조성물 |
WO2017125423A1 (en) * | 2016-01-19 | 2017-07-27 | Janssen Pharmaceutica Nv | Formulations/compositions comprising a btk inhibitor |
CN108653231A (zh) * | 2017-04-01 | 2018-10-16 | 北京赛林泰医药技术有限公司 | 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法 |
SG11202002113TA (en) | 2017-09-26 | 2020-04-29 | Tesaro Inc | Niraparib formulations |
CZ2017787A3 (cs) * | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
CA3089537A1 (en) * | 2018-01-20 | 2019-07-25 | Natco Pharma Limited | Pharmaceutical compositions comprising ibrutinib |
SG11202010642TA (en) | 2018-05-03 | 2020-11-27 | Juno Therapeutics Inc | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
EP3575300A1 (en) | 2018-05-31 | 2019-12-04 | Apotex Inc. | Novel crystalline forms of ibrutinib |
KR20210021348A (ko) | 2018-06-15 | 2021-02-25 | 얀센 파마슈티카 엔.브이. | 이브루티닙을 포함하는 제형/조성물 |
US10688050B1 (en) | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
PE20212323A1 (es) * | 2019-02-22 | 2021-12-14 | Janssen Pharmaceutica Nv | Formulaciones farmaceuticas |
US20210228479A1 (en) * | 2020-01-29 | 2021-07-29 | Farmakeio Nutraceuticals Llc | Steroidal compositions and method of making and use |
US11433072B1 (en) | 2021-06-10 | 2022-09-06 | Hikma Pharmaceuticals USA, Inc. | Oral dosage forms of ibrutinib |
WO2022260667A1 (en) * | 2021-06-10 | 2022-12-15 | Hikma Pharmaceuticals Usa Inc. | Oral dosage forms of ibrutinib |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
Family Cites Families (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
DE3303707A1 (de) | 1983-02-04 | 1984-08-09 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen |
US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
JPH01167840A (ja) | 1987-12-24 | 1989-07-03 | Konica Corp | 新規な写真用シアンカプラー |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
DK0580860T4 (da) | 1991-04-16 | 2005-03-21 | Nippon Shinyaku Co Ltd | Fremgangsmåde til fremstilling af en fast dispersion |
KR100274734B1 (ko) | 1991-11-22 | 2000-12-15 | 제이코버스 코넬리스 레이서 | 리제드로네이트 지연-방출성 조성물 |
US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
DE69332291T2 (de) | 1992-10-16 | 2003-07-31 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung von wachsmatrizes |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
EP0827402A2 (en) | 1995-05-17 | 1998-03-11 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
WO1997049706A1 (en) | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
ATE242245T1 (de) | 1997-03-19 | 2003-06-15 | Basf Ag | Pyrrolo(2,3-d)pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren |
PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
CN1153570C (zh) | 1997-12-31 | 2004-06-16 | 中外制药株式会社 | 制备依曲康唑口服制剂的方法及组合物 |
ATE269295T1 (de) | 1998-04-17 | 2004-07-15 | Parker Hughes Inst | Btk inhibitoren und verfahren zur identifizierung und verwendung |
US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
US7122207B2 (en) | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
US6998233B2 (en) | 1998-06-26 | 2006-02-14 | Sunesis Pharmaceuticals, Inc. | Methods for ligand discovery |
US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
US20050287596A9 (en) | 1998-06-26 | 2005-12-29 | Braisted Andrew C | Novel ligands and libraries of ligands |
UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
ATE400252T1 (de) | 1999-02-10 | 2008-07-15 | Pfizer Prod Inc | Pharmazeutische feste dispersionen |
US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
NZ517758A (en) | 1999-09-17 | 2004-06-25 | Abbott Gmbh & Co | Pyrazolopyrimidines useful as therapeutic agents |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
DE60014130T2 (de) | 1999-10-06 | 2006-03-09 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren |
US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
WO2001041754A2 (en) | 1999-11-30 | 2001-06-14 | Parker Hughes Institute | Inhibitors of collagen-induced platelet aggregation |
JP2003532632A (ja) | 1999-12-17 | 2003-11-05 | アライアッド・ファーマシューティカルズ・インコーポレーテッド | 新規の複素環 |
GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
GB0108903D0 (en) | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
HUP0303656A3 (en) | 2000-10-23 | 2006-03-28 | Bristol Myers Squibb Co | Modulators of bruton's tyrosine kinase, their identification and use |
US20030035833A1 (en) | 2000-12-06 | 2003-02-20 | Xiaorong He | Rapidly dispersing pharmaceutical composition |
US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
US8306897B2 (en) | 2001-05-04 | 2012-11-06 | Stockshield, Inc. | Method and system for insuring against investment loss |
EP1463742A4 (en) | 2001-06-21 | 2006-05-10 | Ariad Pharma Inc | NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES |
US20030119060A1 (en) | 2001-08-10 | 2003-06-26 | Desrosiers Peter J. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
WO2003013540A1 (en) | 2001-08-10 | 2003-02-20 | Novartis Ag | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
WO2003016338A1 (en) | 2001-08-15 | 2003-02-27 | Parker Hughes Institute | Crystal structure of the btk kinase domain |
MXPA04004814A (es) | 2001-11-21 | 2004-08-11 | Sunesis Pharmaceuticals Inc | Metodos para descubrir ligandos. |
US20050084905A1 (en) | 2002-03-21 | 2005-04-21 | Prescott John C. | Identification of kinase inhibitors |
GB2388594A (en) | 2002-05-16 | 2003-11-19 | Bayer Ag | Imidazo-triazine PDE 4 inhibitors |
WO2004014905A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
WO2005000197A2 (en) | 2003-04-11 | 2005-01-06 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
US20050008640A1 (en) | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
US8131475B2 (en) | 2003-09-03 | 2012-03-06 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
EP2157524A3 (en) | 2003-09-03 | 2010-12-08 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods for identifying, diagnosing, and predicting survival of lymphomas |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
AU2004282219C1 (en) | 2003-10-15 | 2009-12-17 | Osi Pharmaceuticals, Inc. | Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors |
US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
US20070281907A1 (en) | 2003-12-22 | 2007-12-06 | Watkins William J | Kinase Inhibitor Phosphonate Conjugates |
US20050153990A1 (en) | 2003-12-22 | 2005-07-14 | Watkins William J. | Phosphonate substituted kinase inhibitors |
UA84903C2 (ru) | 2004-01-08 | 2008-12-10 | Уайет | Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием |
US7855214B2 (en) | 2004-01-26 | 2010-12-21 | Vertex Pharmaceuticals Incorporated | Fused cyclic systems useful as inhibitors of TEC family protein kinases |
WO2005074603A2 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
ITMI20041314A1 (it) | 2004-06-30 | 2004-09-30 | Nuvera Fuel Cells Europ Srl | Dispositivo di raffreddamento per celle a combustibili a membrana |
MY139689A (en) | 2004-07-20 | 2009-10-30 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
EP1794137A4 (en) | 2004-09-27 | 2009-12-02 | Kosan Biosciences Inc | SPECIFIC KINASE INHIBITORS |
EA200700757A1 (ru) | 2004-09-28 | 2007-10-26 | Янссен Фармацевтика Н.В. | Замещённые дипиперидиновые антагонисты ccr2 |
US20060178367A1 (en) | 2004-11-10 | 2006-08-10 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
GB0425035D0 (en) | 2004-11-12 | 2004-12-15 | Novartis Ag | Organic compounds |
CN104688697A (zh) | 2005-03-07 | 2015-06-10 | 拜尔健康护理有限责任公司 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
CA2601628C (en) | 2005-03-10 | 2014-05-13 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
ATE492545T1 (de) | 2005-05-13 | 2011-01-15 | Irm Llc | Verbindungen und zusammensetzungen als proteinkinase-hemmer |
CN101218228A (zh) | 2005-05-23 | 2008-07-09 | 诺瓦提斯公司 | 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式 |
MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US20070065449A1 (en) | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
US20080261975A1 (en) | 2005-11-12 | 2008-10-23 | Joerg Martin Bentzien | Tec Kinase Inhibitors |
US7625880B2 (en) | 2006-01-13 | 2009-12-01 | Pharmacyclics, Inc. | Inhibitors of tyrosine kinases and uses thereof |
WO2007089911A2 (en) | 2006-01-30 | 2007-08-09 | The Scripps Research Institute | Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject |
TW200812611A (en) | 2006-03-20 | 2008-03-16 | Vertex Pharma | Pharmaceutical compositions |
MX2008012929A (es) | 2006-04-04 | 2008-12-17 | Univ California | Antagonistas de cinasa. |
JP5682051B2 (ja) | 2006-05-18 | 2015-03-11 | ファーマサイクリックス,インク. | 細胞内キナーゼ阻害剤 |
DE102006026583A1 (de) | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung |
EP2081435B1 (en) | 2006-09-22 | 2016-05-04 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
US8987233B2 (en) | 2006-11-03 | 2015-03-24 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
FI20080352A0 (fi) | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi |
CN101674813A (zh) | 2007-01-22 | 2010-03-17 | 诺瓦瓦克斯股份有限公司 | 水溶性差的药物的用于减小进食/禁食差异性和改善口服生物利用度的多相药物制剂 |
NL2000640C2 (nl) | 2007-03-05 | 2008-09-08 | Stichting Wetsus Ct Of Excelle | Werkwijze en systeem voor het zuiveren van een vloeistof. |
US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
JP5347202B2 (ja) | 2007-03-28 | 2013-11-20 | ファーマサイクリックス,インク. | ブルトンチロシンキナーゼインヒビター |
US20090010911A1 (en) | 2007-04-06 | 2009-01-08 | Iowa State University Research Foundation, Inc. | Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities |
PE20090422A1 (es) | 2007-04-27 | 2009-04-18 | Purdue Pharma Lp | Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1 |
EP2184984A4 (en) | 2007-07-30 | 2013-07-24 | Ardea Biosciences Inc | N- (ARYLAMINO) ARYLSULFONAMIDE DERIVATIVES COMPRISING POLYMORPHS AS MEK INHIBITORS AND COMPOSITIONS, METHODS OF USE AND PREPARATION METHODS THEREOF |
US7982036B2 (en) | 2007-10-19 | 2011-07-19 | Avila Therapeutics, Inc. | 4,6-disubstitued pyrimidines useful as kinase inhibitors |
CA2701275C (en) | 2007-10-23 | 2016-06-21 | F. Hoffmann-La Roche Ag | Kinase inhibitors |
US8426441B2 (en) | 2007-12-14 | 2013-04-23 | Roche Palo Alto Llc | Inhibitors of bruton's tyrosine kinase |
US20150152115A1 (en) | 2007-12-27 | 2015-06-04 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
CA2749273C (en) | 2008-01-09 | 2018-09-04 | Charleston Laboratories, Inc. | Pharmaceutical oral dosage form comprising a triptan and an antiemetic |
WO2009124982A1 (en) | 2008-04-09 | 2009-10-15 | Lek Pharmaceuticals D.D. | Granulation of active pharmaceutical ingredients |
US8808742B2 (en) | 2008-04-14 | 2014-08-19 | Ardea Biosciences, Inc. | Compositions and methods for preparing and using same |
EP2123626A1 (en) | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
MX360970B (es) | 2008-06-27 | 2018-11-23 | Avila Therapeutics Inc | Compuestos de heteroarilo y usos de los mismos. |
CN102159214A (zh) | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
CA2733001A1 (en) | 2008-07-29 | 2010-02-04 | Frontier Scientific Inc. | Of tetrakis (n-alkylpyridinium) -porphyrin derivatives for killing microbes or preventing growth |
PT2349220E (pt) * | 2008-10-09 | 2012-10-11 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Utilização de solventes orgânicos na granulação húmida de moxifloxacina |
US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
WO2010068806A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
EP2424368B1 (en) | 2009-04-29 | 2014-12-31 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
US9556426B2 (en) | 2009-09-16 | 2017-01-31 | Celgene Avilomics Research, Inc. | Protein kinase conjugates and inhibitors |
US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
PL2578585T3 (pl) | 2010-05-31 | 2017-01-31 | Ono Pharmaceutical Co., Ltd. | Pochodna purynonu jako inhibitor kinazy btk |
US20120071497A1 (en) * | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
NZ717373A (en) | 2010-06-03 | 2017-11-24 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
CA2803056C (en) | 2010-06-23 | 2017-05-16 | Hanmi Science Co., Ltd. | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
CN103096716B (zh) | 2010-08-10 | 2016-03-02 | 西建阿维拉米斯研究公司 | Btk抑制剂的苯磺酸盐 |
MY170189A (en) | 2010-08-12 | 2019-07-09 | Boehringer Ingelheim Int | 6-cycloalkyl-1, 5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
US8541391B2 (en) | 2010-10-28 | 2013-09-24 | Viropharma Incorporated | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole |
US8501484B2 (en) | 2011-03-14 | 2013-08-06 | Los Alamos National Security, Llc | Preparation of cerium halide solvate complexes |
MX2011004759A (es) | 2011-05-04 | 2012-11-21 | Senosiain S A De C V Lab | Nuevas formas solidas de antibioticos. |
JP5974084B2 (ja) | 2011-05-17 | 2016-08-23 | プリンシピア バイオファーマ インコーポレイテッド | チロシンキナーゼ阻害剤 |
BR112014001440A2 (pt) * | 2011-07-18 | 2017-02-21 | Tokai Pharmaceuticals Inc | novas composições e métodos para o tratamento de câncer de próstata |
RS55737B1 (sr) | 2011-09-02 | 2017-07-31 | Incyte Holdings Corp | Heterociklilamini kao inhibitori pi3k |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
WO2013105894A1 (en) | 2012-01-13 | 2013-07-18 | Xspray Microparticles Ab | A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
JP5514256B2 (ja) | 2012-05-18 | 2014-06-04 | 株式会社東芝 | 磁気記憶素子及びその製造方法 |
CN104736178A (zh) | 2012-06-04 | 2015-06-24 | 药品循环公司 | 布鲁顿酪氨酸激酶抑制剂的晶形 |
US20160045503A1 (en) | 2012-06-18 | 2016-02-18 | Principia Biopharma Inc. | Formulations containing reversible covalent compounds |
WO2014004707A1 (en) * | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
CN103121999A (zh) | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
CA2890934A1 (en) | 2012-11-15 | 2014-05-22 | Pharmacyclics, Inc. | Pyrrolopyrimidine compounds as kinase inhibitors |
KR20150141971A (ko) | 2013-04-08 | 2015-12-21 | 파마싸이클릭스 엘엘씨 | 이브루티닙 병용 요법 |
WO2014179528A2 (en) | 2013-05-01 | 2014-11-06 | Brown Dennis M | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
RU2019134551A (ru) | 2013-05-30 | 2019-11-22 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
AR097204A1 (es) | 2013-08-02 | 2016-02-24 | Pharmacyclics Inc | Métodos de tratamiento de tumores sólidos |
US10253244B2 (en) | 2013-09-04 | 2019-04-09 | Halliburton Energy Services, Inc. | Scale-inhibiting cocrystals for treatment of a subterranean formation |
CA2922398C (en) | 2013-09-12 | 2023-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
CN104447701B (zh) | 2013-09-17 | 2019-03-22 | 广东东阳光药业有限公司 | 吡唑类衍生物及其用途 |
AU2014339816B2 (en) | 2013-10-25 | 2020-05-28 | Pharmacyclics Llc | Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy |
WO2015071432A1 (en) | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
CN103694241A (zh) | 2013-11-27 | 2014-04-02 | 苏州晶云药物科技有限公司 | Pci-32765的新晶型a及其制备方法 |
WO2015095772A2 (en) | 2013-12-20 | 2015-06-25 | Emory University | Formulations and methods for targeted ocular delivery of therapeutic agents |
CN105949197A (zh) | 2014-01-29 | 2016-09-21 | 苏州晶云药物科技有限公司 | 依鲁替尼的新晶型及其制备方法 |
CA2938244A1 (en) | 2014-02-07 | 2015-08-13 | Auspex Pharamaceuticals, Inc. | Novel pharmaceutical formulations |
WO2015123654A1 (en) | 2014-02-17 | 2015-08-20 | The Cleveland Clinic Foundation | Amine passivated nanoparticles for cancer treatment and imaging |
US20150238490A1 (en) | 2014-02-21 | 2015-08-27 | Pharmacyclics, Inc. | Biomarkers for predicting response of dlbcl to treatment with ibrutinib |
US20150267752A1 (en) | 2014-03-19 | 2015-09-24 | Roller Bearing Company Of America, Inc. | Bearing outer race having a radially inwardly biased seal |
EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
CA2941087A1 (en) | 2014-03-27 | 2015-10-01 | Perrigo Api Ltd | Ibrutinib solid forms and production process therefor |
CN105085529A (zh) | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
US9127069B1 (en) * | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
US20150110871A1 (en) | 2014-06-02 | 2015-04-23 | David Wong | Gastric retentive tablet compositions |
WO2016007617A2 (en) | 2014-07-09 | 2016-01-14 | Novotec Consulting, Llc. | Pharmaceutical compounding kit |
PT107846B (pt) | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
WO2016020697A1 (en) | 2014-08-06 | 2016-02-11 | Cipla Limited | Pharmaceutical compositions of polymeric nanoparticles |
SG11201700849XA (en) | 2014-08-07 | 2017-03-30 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor |
CA2958139A1 (en) | 2014-08-14 | 2016-02-18 | Assia Chemical Industries Ltd. | Solid state forms of ibrutinib |
WO2016050422A1 (en) | 2014-10-01 | 2016-04-07 | Ratiopharm Gmbh | Acid addition salt of ibrutinib |
CN104523695A (zh) | 2014-11-12 | 2015-04-22 | 广东东阳光药业有限公司 | 一种治疗过度增生性疾病的药物组合物 |
CN105640961A (zh) | 2014-11-18 | 2016-06-08 | 山东瑞禾医药科技有限公司 | 一种含依鲁替尼的药物组合物 |
WO2016079216A1 (en) | 2014-11-20 | 2016-05-26 | Sandoz Ag | Physical forms of ibrutinib, a bruton's kinase inhibitor |
US20150224060A1 (en) | 2015-01-03 | 2015-08-13 | David Wong | Gastric retentive tablet compositions |
CZ201584A3 (cs) | 2015-02-09 | 2016-08-17 | Zentiva, K.S. | Sůl Ibrutinib sulfátu |
JP7149076B2 (ja) | 2015-03-03 | 2022-10-06 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の薬学的製剤 |
WO2016139588A1 (en) | 2015-03-03 | 2016-09-09 | Dr. Reddy's Laboratories Limited | Polymorphs of ibrutinib |
MA41828A (fr) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton |
MA41827A (fr) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton |
CN107873029B (zh) | 2015-04-02 | 2020-09-01 | 拉蒂奥法姆有限责任公司 | 依鲁替尼与羧酸的共晶体 |
KR102632745B1 (ko) | 2015-04-06 | 2024-02-01 | 얀센 파마슈티카 엔브이 | 이브루티닙을 함유하는 조성물 |
CN105294696A (zh) | 2015-11-19 | 2016-02-03 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
CN105440040B (zh) | 2015-12-23 | 2018-03-13 | 浙江京新药业股份有限公司 | 依鲁替尼的纯化方法 |
BR112018014540B1 (pt) * | 2016-01-19 | 2024-02-27 | Janssen Pharmaceutica Nv | Formulações compreendendo inibidor de btk, seus usos e processo para a preparação dos mesmos |
WO2017125423A1 (en) * | 2016-01-19 | 2017-07-27 | Janssen Pharmaceutica Nv | Formulations/compositions comprising a btk inhibitor |
CN105646484A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 晶型b及制备方法 |
CN105646498A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型f及制备方法 |
CN105646499A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型g及制备方法 |
CN106619643A (zh) | 2016-11-11 | 2017-05-10 | 上海雅本化学有限公司 | 一种含依鲁替尼的药物组合物 |
-
2016
- 2016-03-02 JP JP2017541753A patent/JP7149076B2/ja active Active
- 2016-03-02 AU AU2016226279A patent/AU2016226279B2/en active Active
- 2016-03-02 BR BR112017018931A patent/BR112017018931A2/pt not_active Application Discontinuation
- 2016-03-02 CA CA2976695A patent/CA2976695C/en active Active
- 2016-03-02 PT PT167594175T patent/PT3265084T/pt unknown
- 2016-03-02 RS RS20240214A patent/RS65234B1/sr unknown
- 2016-03-02 FI FIEP16759417.5T patent/FI3265084T3/fi active
- 2016-03-02 WO PCT/US2016/020467 patent/WO2016141068A1/en active Application Filing
- 2016-03-02 HR HRP20240231TT patent/HRP20240231T1/hr unknown
- 2016-03-02 TW TW111131798A patent/TW202315634A/zh unknown
- 2016-03-02 IL IL293284A patent/IL293284A/en unknown
- 2016-03-02 TW TW105106446A patent/TWI632912B/zh active
- 2016-03-02 DK DK16759417.5T patent/DK3265084T3/da active
- 2016-03-02 PL PL16759417.5T patent/PL3265084T3/pl unknown
- 2016-03-02 SI SI201631803T patent/SI3265084T1/sl unknown
- 2016-03-02 EP EP23211155.9A patent/EP4338738A2/en active Pending
- 2016-03-02 MX MX2017011270A patent/MX2017011270A/es unknown
- 2016-03-02 TW TW107118387A patent/TWI733027B/zh active
- 2016-03-02 BR BR122023020985-0A patent/BR122023020985A2/pt unknown
- 2016-03-02 CA CA3177995A patent/CA3177995A1/en active Pending
- 2016-03-02 LT LTEPPCT/US2016/020467T patent/LT3265084T/lt unknown
- 2016-03-02 EP EP16759417.5A patent/EP3265084B1/en active Active
- 2016-03-02 SG SG10202102078VA patent/SG10202102078VA/en unknown
- 2016-03-02 CN CN201680016710.0A patent/CN107427498A/zh active Pending
- 2016-03-02 TW TW110121912A patent/TWI810588B/zh active
- 2016-03-02 KR KR1020177026712A patent/KR20170122220A/ko not_active Application Discontinuation
- 2016-03-02 CA CA3177990A patent/CA3177990A1/en active Pending
- 2016-03-02 RU RU2017133990A patent/RU2017133990A/ru unknown
- 2016-03-02 SG SG11201707122QA patent/SG11201707122QA/en unknown
- 2016-03-02 NZ NZ734446A patent/NZ734446A/en unknown
- 2016-03-03 US US15/060,010 patent/US9655857B2/en active Active
-
2017
- 2017-03-23 US US15/467,414 patent/US20170258729A1/en not_active Abandoned
- 2017-08-15 IL IL253995A patent/IL253995B1/en unknown
- 2017-09-04 MX MX2021015370A patent/MX2021015370A/es unknown
- 2017-09-04 MX MX2021015408A patent/MX2021015408A/es unknown
- 2017-09-04 MX MX2021015405A patent/MX2021015405A/es unknown
- 2017-09-04 MX MX2021015368A patent/MX2021015368A/es unknown
-
2018
- 2018-03-01 US US15/909,779 patent/US10010507B1/en active Active
- 2018-05-03 US US15/970,721 patent/US10213386B2/en active Active
- 2018-07-03 HK HK18108569.4A patent/HK1249015A1/zh unknown
- 2018-09-11 US US16/128,312 patent/US20190015340A1/en not_active Abandoned
- 2018-12-20 US US16/228,682 patent/US20190117579A1/en not_active Abandoned
-
2019
- 2019-11-19 ZA ZA2019/07661A patent/ZA201907661B/en unknown
-
2020
- 2020-04-10 US US16/846,064 patent/US10828259B2/en active Active
-
2021
- 2021-09-30 AU AU2021240244A patent/AU2021240244B2/en active Active
- 2021-11-29 US US17/536,701 patent/US20220331252A1/en active Pending
-
2022
- 2022-06-30 JP JP2022106400A patent/JP2022141701A/ja active Pending
-
2023
- 2023-05-01 AU AU2023202671A patent/AU2023202671A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018507200A5 (ja) | ||
JP2022141701A5 (ja) | ||
NZ734446A (en) | Pharmaceutical formulations of bruton’s tyrosine kinase inhibtor | |
US9545402B2 (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-y1]-1H-quinolin-2-one lactate monohydrate | |
JP2017525712A5 (ja) | ||
JP2017222705A5 (ja) | ||
RU2006133902A (ru) | Твердые препаративные формы оспемифена | |
JP2007523210A5 (ja) | ||
JP2007091758A5 (ja) | ||
JP2014533733A5 (ja) | ||
JP2010132654A5 (ja) | ||
SI3082773T1 (en) | Oral formulations of pyrrolidine derivatives | |
JP2008503540A5 (ja) | ||
JP2016518398A (ja) | 低用量医薬組成物 | |
JP2008500287A5 (ja) | ||
CA2569683A1 (en) | Oral antimicrobial pharmaceutical compositions | |
US20150366807A1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
JP2021512869A5 (ja) | ||
NO20091644L (no) | Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist | |
JP2013502452A (ja) | オチロニウムの直接圧縮錠 | |
WO2007049291A1 (en) | Novel solid dosage forms of valsartan and rochlorothiazide | |
RU2019144196A (ru) | Фармацевтическая композиция, содержащая ремоглифлозин и противодиабетическое средство | |
US20120035177A1 (en) | Tablet formulation for p38 inhibitor and method | |
AU2016231883A1 (en) | Pharmaceutical compositions of dimethyl fumarate | |
WO2017037645A1 (en) | Stable pharmaceutical formulations of teriflunomide |